Major Events - JD Industrial (07618) received a subscription rate of 60.52 times for its public offering in Hong Kong, with a share price set at HKD 14.10 [1] - Shanghai Pharmaceuticals (02607) obtained approval for the listing application of Succinic Acid Sultamicillin Tablets (SPH3127) [1] - Fosun Pharma (02196) received approval from the National Medical Products Administration for the drug registration application of Sodium Phosphonate Injection [1] - Lingbao Gold (03330) subsidiary plans to invest AUD 370 million to acquire a 50%+1 share stake in St Barbara Mining Pty Ltd [1] - Jiangsu Ninghu Expressway (00177) intends to increase capital by CNY 3.26964 billion to Longtan Bridge Company [1] - Yunfeng Financial (00376) had Fitch maintain the "A-" (Strong) financial strength rating for Wantong Insurance [1] Operating Performance - Sunny Optical Technology (02382) reported a shipment volume of 12.634 million vehicle-mounted lenses in November, a year-on-year increase of 69.4% [1] - Q Technology (01478) saw mobile camera module sales of 38.053 million units in November, a month-on-month decrease of 13.6% and a year-on-year decrease of 5.6% [1] - Yue Yuen Industrial (00551) reported a cumulative operating profit of approximately USD 7.382 billion for the first 11 months, a year-on-year decrease of 1.6% [1] - Baoshan International (03813) reported a cumulative operating profit of CNY 15.784 billion for the first 11 months, a year-on-year decline of 6.8% [1] - COFCO Joycome (01610) reported a pig slaughter volume of 559,000 heads in November, a month-on-month decrease of 4.44% [1]

Core Insights - Shanghai Pharmaceuticals (02607) announced that its subsidiary, Shanghai Shenyin Pharmaceutical Factory, received the drug registration certificate for SPH3127 (also known as Apixaban) from the National Medical Products Administration [1][2] - SPH3127 is a new generation oral non-peptide small molecule renin inhibitor, designed to treat primary hypertension by directly inhibiting renin, counteracting the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - Clinical studies have shown that SPH3127 has a good overall safety profile and significant antihypertensive efficacy in patients with primary hypertension, providing a new treatment option for this patient group [1] Company Developments - The approval of SPH3127 marks Shanghai Shenyin's qualification to produce and sell the drug in the domestic market [2] - The company emphasizes the importance of drug research and development, maintaining strict quality and safety controls throughout the drug development, manufacturing, and sales processes [2] - The total research and development investment for SPH3127 has reached approximately 296 million yuan [1]

Core Viewpoint - Shanghai Pharmaceuticals (02607.HK) has received approval from the National Medical Products Administration for its new drug, SPH3127 tablets, which are a new generation of oral non-peptide small molecule renin inhibitors for the treatment of primary hypertension [1] Company Summary - The drug SPH3127 is designed to directly inhibit renin, counteracting the increase in blood pressure caused by the overactivation of the renin-angiotensin-aldosterone system (RAAS) [1] - The approval of SPH3127 represents a significant advancement in the company's product offerings in the hypertension treatment market [1] Industry Summary - The approval of new hypertension treatments like SPH3127 reflects ongoing innovation in the pharmaceutical industry, particularly in the development of targeted therapies for cardiovascular conditions [1] - The introduction of non-peptide small molecule inhibitors may enhance treatment options for patients with primary hypertension, potentially impacting market dynamics [1]